natgillin/translations-raw huggingface dataset:
If ritonavir is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. 
Če ritonavir uporabite sočasno s parenteralnim midazolamom, morate to izvesti v enoti za intenzivno nego (EIN) ali podobnem okolju, ki omogoča natančno klinično spremljanje in ustrezno medicinsko ukrepanje v primeru depresije dihanja in/ali podaljšane sedacije.
However, because ritonavir has also been shown to inhibit CYP2B6 in vitro, the recommended dose of bupropion should not be exceeded. 
Ker pa je tudi ugotovljeno, da ritonavir in vitro zavira CYP2B6, priporočenega odmerka bupropiona ne smete prekoračiti.
developing viral resistance (in HIV-postive infants) and (3) serious adverse reactions in a breastfed infant, HIV infected women should not breast feed their infants under any circumstances if they are receiving ritonavir. 
Zaradi možnosti (1) prenosa virusa HIV (pri HIV negativnih dojenčkih), (2) razvoja virusne rezistence (pri HIV pozitivnih dojenčkih) in (3) resnih neželenih učinkov pri dojenem otroku, ženske, okužene z virusom HIV, v nobenem primeru ne smejo dojiti svojih otrok, če prejemajo ritonavir.
Patients receiving ritonavir or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV-1 infection. 
Bolnikom, ki dobivajo ritonavir ali kakšno drugo protiretrovirusno zdravilo, se lahko še naprej pojavljajo oportunistične okužbe in drugi zapleti okužbe s HIV-1.
600, single 
600, posamičen
If a patient is already taking St John's wort, St John's wort should be stopped and if possible check viral levels. 
Če bolnik že jemlje šentjanževko, je treba njeno jemanje prekiniti in, če je mogoče, kontrolirati raven virusov.
Amphetamine derivatives Amphetamine 
Derivati amfetamina
Upon multiple dosing, ritonavir accumulation is slightly less than predicted from a single dose due to a time and dose-related increase in apparent clearance (Cl/F). 
Po večkratnem odmerjanju je kopičenje ritonavirja rahlo večje, kot bi predvidevali na podlagi enkratnega odmerka, in sicer zaradi časa ter z odmerkom povezanega zvečanja navideznega očistka (Oč/F).
Taking Ritonavir Mylan with food and drink 
Jemanje zdravila Ritonavir Mylan skupaj s hrano in pijačo
Mylan Hungary Kft, Mylan utca 1, Komárom, H-2900 Hungary 
Mylan utca 1, Komárom, H-2900
Ritonavir binds to both human alpha 1-acid glycoprotein (AAG) and human serum albumin (HSA) with comparable affinities. 
Ritonavir se veže na humani alfa-1-kisli glikoprotein (AAG) in na humani serumski albumin (HSA) s primerljivima afinitetama.
Therefore, the use of ritonavir is not recommended in patients receiving rivaroxaban. 
Zato ritonavirja ni priporočljivo uporabljati pri bolnikih, ki prejemajo rivaroksaban.
Adverse reactions in clinical studies and post-marketing in adult patients System Order Class 
Neželeni učinki v kliničnih študijah in pomarketinškem obdobju pri odraslih bolnikih Organski sistem
Diarrhoea or vomiting that is not improving (persistent), as this may reduce how well the medicines you are taking work. 
driska ali bruhanje, ki se ne popravi (traja), ker to lahko vpliva na delovanje zdravil, ki jih jemljete.
For patients who have completed the ramp-up phase and are on a steady daily dose of venetoclax, reduce the venetoclax dose by at least 75% when used with strong CYP3A inhibitors (refer to the venetoclax SmPC for dosing instructions). 
Za bolnike, ki so zaključili fazo povečevanja odmerka in prejemajo stalen dnevni odmerek venetoklaksa, zmanjšajte odmerek venetoklaksa za najmanj 75 %, kadar je ta uporabljen z močnimi zaviralci CYP3A (glejte povzetek glavnih značilnosti zdravila za venetoklaks).
↑ 20 to 39% 
Nelfinavir ↑ 20-39 % ND
Always keep enough Ritonavir Mylan on hand so you don't run out. 
Vedno imejte pri roki dovolj zdravila Ritonavir Mylan, da vam ga ne bo zmanjkalo.
Note: ritonavir was dosed after a meal for all listed regimens. 
Opomba: ritonavir je bil v vseh navedenih shemah uporabljen po obroku.
These data indicate no increase in the rate of birth defects compared to rates observed in population-based birth defect surveillance systems. 
Ti podatki ne kažejo večjega deleža prirojenih hib kot je delež, ugotovljen s sistemi populacijskega nadzora prirojenih hib.
In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products. 
Pri sočasnem protivirusnem zdravljenju proti hepatitisu B ali C je treba upoštevati tudi ustrezne informacije o teh zdravilih.
Inhibition of HIV protease renders the enzyme incapable of processing the gag-pol polyprotein precursor which leads to the production of HIV particles with immature morphology that are unable to initiate new rounds of infection. 
Zavrtje HIVproteaz encimu onemogoči obdelavo poliproteinskega predhodnika gag-pol; tako nastajajo morfološko nezreli delci HIV, nezmožni za sprožanje novih ciklusov okužbe.
After multiple dosing of ritonavir to healthy volunteers (500 mg twice daily) and subjects with mild to moderate hepatic impairment (Child Pugh Class A and B, 400 mg twice daily) exposure to ritonavir after dose normalisation was not significantly different between the two groups. 
Po večkratnem odmerjanju ritonavirja pri zdravih prostovoljcih (500 mg dvakrat na dan) in preiskovancih z blago do zmerno okvaro jeter (razreda A in B po Child Pughu, 400 mg dvakrat na dan) se izpostavljenost ritonavirju po normalizaciji odmerka med skupinama ni pomembno razlikovala.
Tell your doctor if you are taking any of the medicines listed below, as special care should be taken. 
Zdravniku morate povedati, če jemljete katero od naslednjih zdravil, ker je v takšnem primeru potrebna posebna previdnost.
* Your doctor may decide that you can take rifabutin and/or voriconazole with a booster (lower dose) of ritonavir but a full dose of ritonavir must not be taken together with these two medicines. 
* Zdravnik bo morda presodil, da lahko rifabutin in/ali vorikonazol jemljete s spodbujevalnim (nižjim) odmerkom ritonavirja; ne smete pa skupaj s tema zdraviloma jemati polnega odmerka ritonavirja.
Ritonavir Mylan should be taken every day to help control your HIV, no matter how much better you feel. 
Da bo okužba s HIV obvladana, morate zdravilo Ritonavir Mylan jemati vsak dan, ne glede na to, koliko bolje se počutite.
Thereby, increasing the potential for sildenafil-associated adverse events (which include hypotension and syncope). 
Zaradi tega večja možnost neželenih učinkov sildenafila (vključno s hipotenzijo in sinkopo).
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g., beclomethasone). 
V poštev pride zmanjšanje glukokortikoida, ob čemer je treba natančno kontrolirati lokalne in sistemske učinke, ali pa prehod na glukokortikoid, ki ni substrat CYP3A4 (npr. beklometazon).
The effects of ritonavir (alone or combined with other antiretroviral agents) on biological markers of disease activity such as CD4 cell count and viral RNA were evaluated in several studies involving HIV-1 infected patients. 
Učinke ritonavirja (samega ali v kombinaciji z drugimi protiretrovirusnimi učinkovinami) na biološke označevalce aktivnosti bolezni, npr. število celic CD4 in virusno RNA, so ocenili v več študijah bolnikov, okuženih s HIV-1.
This increase is likely due to ritonavir and a more pronounced effect may be observed during prolonged co-administration. 
To povečanje je verjetno posledica jemaanja ritonavirja in bolj izrazit učinek se lahko opazi med podaljšano sočasno uporabo.
Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3 - 4 fold increase in midazolam plasma levels. 
Podatki o sočasni uporabi parenteralnega midazolama z drugimi zaviralci proteaz nakazujejo možno 3- do 4-kratno zvišanje koncentracije midazolama v plazmi.
Hepatic changes involved hepatocellular, biliary and phagocytic elements and were accompanied by increases in hepatic enzymes. 
Spremembe na jetrih so obsegale hepatocelularne, biliarne in fagocitne elemente in jih je spremljalo zvišanje jetrnih encimov.
30 film-coated tablets 90 film-coated tablets 100 film-coated tablets 
30 filmsko obloženih tablet 90 filmsko obloženih tablet 100 filmsko obloženih tablet
When you travel or need to stay in the hospital, make sure you have enough Ritonavir Mylan to last until you can get a new supply. 
Če greste na potovanje ali v bolnišnico, morate imeti s seboj vedno toliko zdravila Ritonavir Mylan, da bo zaloga trajala, dokler ne dobite nove.
In the event of unexplained or continual muscle pain, tenderness, weakness or cramps, stop taking the medicine, contact your doctor as soon as possible or go to the Accident and Emergency Department of your nearest hospital. 
V primeru nepojasnjenih ali stalnih bolečin v mišicah, občutljivosti ali šibkosti mišic ali krčev v mišicah nehajte jemati to zdravilo, se čim prej obrnite na svojega zdravnika, ali pojdite v ambulanto za nujno medicinsko pomoč najbližje bolnišnice.
Ritonavir should be used with caution in such patients (see section 5.1). 
Ritonavir morate pri takšnih bolnikih uporabljati previdno (glejte poglavje 5.1).
Co-administration of saquinavir and ritonavir has led to severe adverse reactions, mainly diabetic ketoacidosis and liver disorders, especially in patients with pre-existing liver disease. 
Sočasna uporaba sakinavirja in ritonavirja je povzročila hude neželene učinke, predvsem diabetično ketoacidozo in jetrne motnje, zlasti pri bolnikih z že obstoječo boleznijo jeter.
However, these warnings may also apply when Ritonavir Mylan is used in lower doses (a booster) with other medicines. 
Vendar pa lahko ta opozorila veljajo tudi med uporabo zdravila Ritonavir Mylan v manjših (spodbujevalnih) odmerkih skupaj z drugimi zdravili.
Ritonavir-resistant isolates of HIV-1 have been selected in vitro and isolated from patients treated with therapeutic doses of ritonavir. 
Izolati HIV-1, odporni proti ritonavirju, so bili selekcionirani in vitro in izolirani pri bolnikih, zdravljenih s terapevtskimi odmerki ritonavirja.
Tell your doctor if you have a heart defect or conduction defect. 
Zdravniku morate povedati, če imate kakšno srčno napako ali prevodno motnjo v srcu.
Pancreatitis should be considered if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of pancreatitis should occur. 
Na pankreatitis je treba pomisliti, če se pojavijo klinični simptomi (navzea, bruhanje, bolečine v trebuhu) ali nenormalne laboratorijske vrednosti (npr. zvišanje serumske lipaze ali amilaze), ki nakazujejo pankreatitis.
Extra monitoring is recommended when diarrhoea occurs. 
Dodaten nadzor je priporočljiv, če se pojavi driska.
Diabetes, as there have been reports of worsening of or the development of diabetes (diabetes mellitus) in some patients taking protease inhibitors. 
sladkorno bolezen, kajti opisani so primeri poslabšanja ali pojava sladkorne bolezni (diabetesa mellitusa) pri nekaterih bolnikih, ki so jemali zaviralce proteaz.
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
There are some medicines you cannot take at all with ritonavir. 
Nekaterih zdravil sploh ne smete jemati skupaj z ritonavirjem.
No subject experienced an increase in QTcF of ≥ 60 msec from baseline or a QTcF interval exceeding the potentially clinically relevant threshold of 500 msec. 
Nobenemu preiskovancu se QTcF ni podaljšal za  60 msec v primerjavi z izhodiščem, dolžina intervala QTcF pa ni pri nobenem presegla potencialno klinično pomembnega praga 500 msec.
For selected medicinal products (e.g. alprazolam) the inhibitory effects of ritonavir on CYP3A4 may decrease over time. 
Pri nekaterih zdravilih (npr. pri alprazolamu) se lahko zaviralni učinki ritonavirja na CYP3A4 sčasoma zmanjšajo.
Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
These data largely refer to exposures where ritonavir was used in combination therapy and not at therapeutic ritonavir doses but at lower doses as a pharmacokinetic enhancer for other PIs. 
Ti podatki se v glavnem nanašajo na izpostavljenost v primerih, ko je bil ritonavir uporabljen v kombinirani terapiji: ne v terapevtskih odmerkih ritonavirja, temveč v manjših odmerkih kot farmakokinetični stopnjevalec drugih zaviralcev proteaz.
Ritonavir Mylan should be administered by physicians who are experienced in the treatment of HIV infection. 
Ritonavir Mylan morajo predpisovati zdravniki, ki imajo izkušnje z zdravljenjem okužbe s HIV.
What Ritonavir Mylan is and what it is used for What you need to know before you or your child takes Ritonavir Mylan How to take Ritonavir Mylan 
Kaj je zdravilo Ritonavir Mylan in za kaj ga uporabljamo Kaj morate vedeti, preden boste vi ali vaš otrok vzeli zdravilo Ritonavir Mylan Kako jemati zdravilo Ritonavir Mylan
Ultrastructural evidence suggests that these retinal changes may be secondary to phospholipidosis. 
Ultrastrukturni izsledki nakazujejo, da so lahko ugotovljene mrežnične spremembe drugotne, nastale zaradi fosfolipidoze.
Patients with advanced HIV disease may be at risk of elevated triglycerides and pancreatitis (see section 4.4). 
Bolnike z napredovalo boleznijo HIV utegneta ogrožati zvišanje trigliceridov in pankreatitis (glejte poglavje 4.4).
Based on interaction studies with the ritonavir boosted protease inhibitors (lopinavir/ritonavir, atazanavir), concurrent administration of omeprazole or ranitidine does not significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of exposure (about 6 - 18%). 
Na podlagi študij medsebojnega delovanja zaviralcev proteaz, ojačenih z ritonavirjem (lopinavir/ritonavir, atazanavir), sočasna uporaba omeprazola ali ranitidina na učinkovitost ritonavirja kot farmakokinetičnega stopnjevalca ne vpliva signifikantno, čeprav se izpostavljenost rahlo spremeni (okoli 6-18 %).
The following warnings apply when Ritonavir Mylan is taken as a full dose. 
Naslednja opozorila veljajo, če jemljete zdravilo Ritonavir Mylan v polnem odmerku.
Some patients taking ritonavir can develop serious problems with their pancreas. 
Nekaterim bolnikom, ki jemljejo ritonavir, se lahko pojavijo resne težave s trebušno slinavko.
Digoxin levels should be monitored more intensively than usual during this period, with dose adjustments made, as necessary, based on clinical, electrocardiographic and digoxin level findings. 
Med tem obdobjem je treba koncentracijo digoksina kontrolirati intenzivneje kot ponavadi, odmerek pa prilagajati, kot je potrebno glede na klinični in elektrokardiografski izvid ter koncentracijo digoksina.
Ritonavir is used in combination with other anti-HIV medicines (antiretrovirals) to control your HIV infection. 
Ritonavir uporabljamo v kombinaciji z drugimi zdravili proti HIV (protiretrovirusnimi zdravili) za obvladovanje okužbe s HIV.
The pharmacokinetic parameters observed with various dosing schemes of ritonavir alone are shown in the table below. 
Farmakokinetični parametri, zabeleženi z različnimi odmernimi shemami samega ritonavirja, so prikazani v spodnji tabeli.
In an interaction study of single-dose bedaquiline and multiple dose lopinavir/ritonavir, the AUC of bedaquiline was increased by 22%. 
V študiji medsebojnega delovanja, v kateri so preiskovanci prejeli enkraten odmerek bedakilina in več odmerkov lopinavirja/ritonavirja, se je AUC bedakilina povečala za 22 %.
Induction of CYP1A2 and CYP2C9 lead to decreased levels of R-warfarin while little pharmacokinetic effect is noted on S-warfarin when co-administered with ritonavir. 
Indukcija CYP1A2 in CYP2C9 povzroči znižanje koncentracije R-varfarina, medtem ko na farmakokinetiko S-varfarina sočasna uporaba ritonavirja vpliva le malo.
Ritonavir is recommended for children 2 years of age and older. 
Ritonavir je priporočljiv za otroke, stare 2 leti ali več.
These are listed earlier in section 2, under ‘Do not take Ritonavir Mylan'. 
Ta zdravila so našteta zgoraj, v poglavju 2 pod naslovom “Ne jemljite zdravila Ritonavir Mylanˮ.
Therefore, combination of bedaquiline with ritonavir should be avoided. 
Zato se je treba izogibati kombinaciji bedakilina z ritonavirjem.
Co-administration with ritonavir may cause a large increase in the concentration of this benzodiazepine. 
Sočasna uporaba ritonvirja lahko zelo zviša koncentracijo tega benzodiazepina.
Ritonavir has a high affinity for several cytochrome P450 (CYP) isoforms and may inhibit oxidation with the following ranked order: CYP3A4 > CYP2D6. 
Ritonavir ima veliko afiniteto za več izooblik citokroma P450 (CYP) in lahko zavre oksidacijo po naslednjem zaporedju: CYP3A4 > CYP2D6.
Although rifampicin may induce metabolism of ritonavir, limited data indicate that when high doses of ritonavir (600 mg twice daily) is co-administered with rifampicin, the additional inducing effect of rifampicin (next to that of ritonavir itself) is small and may have no clinical relevant effect on ritonavir levels in high-dose ritonavir therapy. 
Rifampicin lahko inducira presnovo ritonavirja, vendar omejeni podatki kažejo, da je ob sočasni uporabi visokih odmerkov ritonavirja (600 mg dvakrat dnevno) in rifampicina dodatni inducirajoči vpliv rifampicina (poleg ritonavirja samega) majhen in v primeru visokoodmerne terapije z ritonavirjem nima klinično pomembnega vpliva na koncentracijo ritonavirja.
Ritonavir Mylan film-coated tablets are administered orally and should be ingested with food (see section 5.2). 
Filmsko obložene tablete Ritonavir Mylan se uporabljajo peroralno in se morajo jemati s hrano (glejte poglavje 5.2).
Adult Use 
Uporaba pri odraslih
Calcium channel antagonists 
Antagonisti kalcijevih kanalčkov
The continuation of ritonavir therapy should be evaluated by viral load because of the possibility of the emergence of resistance as described under section 4.1. 
Nadaljevanje zdravljenja z ritonavirjem je treba ocenjevati z virusnim bremenom, ker obstaja možnost odpornosti, kot je opisano v poglavju 4.1 Terapevtske indikacije.
Due to the solubility characteristics and possibility of transintestinal elimination, it is proposed that management of overdose could entail gastric lavage and administration of activated charcoal. 
Zaradi topnostnih značilnosti in možnosti transintestinalnega izločanja naj bi zdravljenje prevelikega odmerjanja obsegalo izpiranje želodca in uporabo aktivnega oglja.
Low doses of ritonavir have shown profound effects on the pharmacokinetics of other protease inhibitors (and other products metabolised by CYP3A4) and other protease inhibitors may influence the pharmacokinetics of ritonavir (see section 4.5). 
Majhni odmerki ritonavirja so pokazali močne učinke na farmakokinetiko drugih zaviralcev proteaz (in drugih zdravil, ki se presnavljajo s CYP3A4), drugi zaviralci proteaz pa lahko vplivajo na farmakokinetiko ritonavirja (glejte poglavje 4.5).
These effects are thought to represent induction of bupropion metabolism. 
Domnevno gre za posledico indukcije presnove bupropiona.
Ritonavir Mylan is not recommended in children below 2 years of age. 
Zdravilo Ritonavir Mylan ni priporočljivo za otroke, mlajše od 2 let.
If treatment with an HMGCoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5). 
Če je indicirano zdravljenje z zaviralcem reduktaze HMG-CoA, sta priporočljiva pravastatin ali fluvastatin (glejte poglavje 4.5).
All thyroid changes were reversible upon discontinuation of ritonavir. 
Vse spremembe na ščitnici so bile po prekinitvi ritonavirja reverzibilne.
Inform your doctor as soon as possible if you experience any symptoms that suggest an allergic reaction after taking Ritonavir Mylan such as rash, hives or breathing difficulties. 
Zdravnika morate čimprej obvestiti, če se vam po jemanju zdravila Ritonavir Mylan pojavijo simptomi, ki kažejo na alergijsko reakcijo, npr. izpuščaj, koprivnica ali težave z dihanjem.
Ritonavir also has a high affinity for P-glycoprotein and may inhibit this transporter. 
Ritonavir ima tudi veliko afiniteto za P-glikoprotein in lahko zavre ta prenašalec.
Animal studies as well as in vitro experiments with human hepatic microsomes indicated that ritonavir primarily underwent oxidative metabolism. 
Študije na živalih in poskusi s človeškimi jetrnimi mikrosomi in vitro kažejo, da je presnova ritonavirja predvsem oksidacijska.
Ritonavir 100 mg twice daily with saquinavir 1,000 mg twice daily provides saquinavir systemic exposure over 24 hours similar to or greater than those achieved with saquinavir 1,200 mg three times daily without ritonavir. 
Ritonavir 100 mg dvakrat na dan s sakvinavirjem 1000 mg dvakrat na dan zagotavlja 24-urno sistemsko izpostavljenost sakvinavirju, ki je podobna ali večja, kot je dosežena s 1200 mg sakvinavirja trikrat na dan brez ritonavirja.
The relatively high frequency of diarrhoea during treatment with ritonavir may compromise the absorption and efficacy (due to decreased compliance) of ritonavir or other concurrent medicinal products. 
Razmeroma velika pogostnost driske med zdravljenjem z ritonavirjem lahko ogrozi absorpcijo in (zaradi zmanjšane sodelovalnosti bolnika) učinkovitost ritonavirja ali drugih sočasno uporabljanih zdravil.
If you realise you have taken more Ritonavir Mylan than you were supposed to, contact your doctor or the Accident and Emergency Department of your nearest hospital straight away. 
Če ugotovite, da ste vzeli več zdravila Ritonavir Mylan, kot bi smeli, se takoj obrnite na svojega zdravnika ali na oddelek za nujno pomoč najbližje bolnišnice.
Treatment should be initiated at 300 mg (3 tablets) twice daily for a period of three days and increased by 100 mg (1 tablet) twice daily increments up to 600 mg twice daily over a period of no longer than 14 days. 
Zdravljenje je treba začeti s 300 mg (3 tablete) dvakrat na dan v obdobju 3 dni in odmerek zvečevati po 100 mg (1 tableta) dvakrat na dan do 600 mg dvakrat na dan v obdobju, ki ne presega 14 dni.
One patient in clinical trials took ritonavir 1,500 mg/day for two days and reported paraesthesia, which resolved after the dose was decreased. 
V kliničnih preskušanjih je en bolnik dva dni jemal 1.500 mg ritonavirja na dan; navajal je parestezije, ki so po zmanjšanju odmerka izginile.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice. 
Pri bolnikih z obstoječo disfunkcijo jeter (vključno s kroničnim aktivnim hepatitisom) se med kombiniranim protiretrovirusnim zdravljenjem pogosteje pojavijo nepravilnosti v delovanju jeter, zato jih je treba kontrolirati skladno s standardno prakso.
Haemophiliac patients should therefore be made aware of the possibility of increased bleeding. 
Bolnike s hemofilijo je treba seznaniti z možnostjo, da se zveča nagnjenost h krvavitvam.
The tablets should be swallowed whole and not chewed, broken or crushed. 
Tablete je treba pogoltniti cele in se jih ne sme žvečiti, prelomiti ali zdrobiti.
Antipsychotics/ Neuroleptics 
Antipsihotiki/Nevroleptiki
Medicinal products that are affected by the use of ritonavir 
Zdravila, na katera vpliva uporaba ritonavirja
No interaction study is available with ritonavir only. 
Študij medsebojnega delovanja samo z ritonavirjem ni na razpolago.